Harnessing the power of NEXT GENERATION ADCs to fight cancer

About US

Tallac Therapeutics™ is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer using antibody drug conjugates (ADCs). Tallac’s pipeline of oligonucleotide-based ADC candidates includes novel Toll-like Receptor Agonist Antibody Conjugates (TRAAC) to systemically deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) and trigger immune activation within the tumor microenvironment. Several TRAAC molecules are in various stages of discovery and development, including two programs in the clinic.



Tallac’s novel technology allows precise conjugation of therapeutic oligo payloads, expanding beyond the conventional toxin payloads and enabling the precise and systemic delivery of next gen therapies such as CpG oligonucleotides (TLR9 Agonist), antisense oligonucleotides, and siRNA.


We are excited to share our latest news and scientific publications.

Tallac Presents First Clinical Data for TAC-001 at SITC 2023

~ Marks the First Clinical Data for a Systemically Administered TLR9 Agonist Antibody Conjugate (TRAAC)…

Tallac Therapeutics Announces Two Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

BURLINGAME, Calif. – (BUSINESS WIRE) – September 27, 2023 — Tallac Therapeutics, Inc., a privately held biopharmaceutical…